(Reuters) - Hisun and UBS declined to comment.
Trading in the Shanghai-listed shares of Hisun Pharmaceutical, a business partner of U.S. drug maker Eli Lilly and Co. , was suspended on Thursday pending announcement on a major transaction.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment